DRAFT MONOGRAPH ON SOFOSBUVIR TABLETS
(SOFOSBUVIRI COMPRESSI)

Draft Proposal for inclusion in The International Pharmacopoeia
(November 2019)

DRAFT FOR COMMENTS

Please send any comments you may have on this draft working document to Dr Herbert Schmidt, Technical Officer, Medicines Quality Assurance, Technologies Standards and Norms (email: schmidt@who.int) by 20 February 2020.

Working documents are sent out electronically and they will also be placed on the WHO Medicines website (http://www.who.int/medicines/areas/quality_safety/quality_assurance/guidelines/en/) for comments under the “Current projects” link. If you wish to receive our draft guidelines, please send your e-mail address to jonessi@who.int and your name will be added to our electronic mailing list.

© World Health Organization 2019

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:
Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland, e-mail: kopps@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.

However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/19.798:

SOFOSBUVIR TABLETS
(SOFOSBUVIRI COMPRESSI)

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>First draft received from collaborating laboratory.</td>
<td>April 2019</td>
</tr>
<tr>
<td>Discussion at the consultation on Screening Technologies, Laboratory Tools and Pharmacopoeial Specifications for Medicines</td>
<td>2-3 May 2019</td>
</tr>
<tr>
<td>Discussion at the Fifty-fourth meeting of the Expert Committee on Specifications for Pharmaceutical Preparations.</td>
<td>14-18 October 2019</td>
</tr>
<tr>
<td>Discussion at the consultation on Screening Technologies, Laboratory Tools and Pharmacopoeial Specifications for Medicines.</td>
<td>2020</td>
</tr>
<tr>
<td>Further follow-up action as required.</td>
<td></td>
</tr>
</tbody>
</table>
DRAFT PROPOSAL FOR INCLUSION IN
THE INTERNATIONAL PHARMACOPOEIA
SOFOSBUVIR TABLETS
(SOFOSBUVIRI COMPRESSI)

Category. Antiviral (Hepatitis C viral polymerase nucleotide inhibitor)

Storage. Sofosbuvir tablets should be kept in a well-closed container not exceeding 30 °C.

Additional information. Strength in the current WHO Model List of Essential Medicines: 400 mg sofosbuvir.

Requirements

Comply with the monograph for “Tablets”.

Definition. Sofosbuvir tablets contain not less than 90.0 % and not more than 110.0 % of the amount of sofosbuvir (C_{22}H_{29}FN_{3}O_{9}P) stated on the label.

Identity tests

- Either test A alone or tests B and D or tests C and D may be applied.

A. Carry out the test as described under 1.14.4 High-performance liquid chromatography using the conditions given under “Assay”. Record the UV spectrum of the principle peak in the chromatograms with a diode array detector in the range of 200 nm to 400 nm. The retention time and the UV spectrum of the principal peak in the chromatogram obtained with solution (1) correspond to the retention time and UV spectrum of the peak due to sofosbuvir in the chromatogram obtained with solution (2).

B. Carry out the test as described under 1.14.4 High-performance liquid chromatography using the conditions given under “Assay”. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to sofosbuvir in the chromatogram obtained with solution (2).
C. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R2 as the coating substance and a mixture of 6 volumes of dichloromethane R, 1 volume of methanol R, 4 volumes of ethyl acetate R and 0.1 volume of ammonia R as the mobile phase.

Apply separately to the plate 10 µL of each of the following solutions in methanol R. For solution (A), sonicate a quantity of the powdered tablets, nominally containing 10 mg of sofosbuvir with 10 mL of methanol, allow to cool to room temperature and filter. For solution (B), use 1 mg of sofosbuvir RS per mL. After removing the plate from the chromatographic chamber, allow it to dry exhaustively in a current of air. Examine the chromatogram in ultraviolet light (254 nm). The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

D. To a quantity of the powdered tablets, nominally equivalent to 50 mg of sofosbuvir, add 30 mL of methanol R and sonicate for 10 minutes. Allow to cool to room temperature, dilute to 50 mL with the same solvent and filter. Dilute 1.0 mL of the filtrate to 100.0 mL using methanol R. The absorption spectrum (1.6) of the resulting solution, when observed between 200 and 400 nm, exhibits a maximum at about 260 nm.

**Dissolution.** Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as dissolution medium 900 mL of dissolution buffer pH 6.8 TS. Rotate the paddle at 75 revolutions per minute. At 15 minutes, withdraw a sample of 10 mL of the medium through an in-line filter. Allow the filtered solution to cool down to room temperature. Dilute 5.0 mL of the filtrate to 50.0 mL with dissolution medium and use it as solution (1). For solution (2), transfer 44.0 mg of sofosbuvir RS to a 100 mL volumetric flask. Add 4 mL of methanol R and 70 mL of dissolution medium, sonicate for 5 minutes, cool to room temperature and dilute to volume. Dilute 5.0 mL of this solution to 50.0 mL with dissolution medium.

Measure the absorbance as described under 1.6 Spectrophotometry in the visible and ultraviolet regions of a 1 cm layer of the resulting solutions at the maximum at about 262 nm, using the dissolution medium as the blank.

---

1 Silica gel on TLC Alu foils from Fluka is suitable.
For each of the tablets tested, calculate the total amount of sofosbuvir ($C_{22}H_{29}FN_3O_9P$) in the medium. Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria. The amount of sofosbuvir released is not less than 75% (Q) of the amount declared on the label.

[Note from the Secretariat. It is intended to determine the absorptivity value of sofosbuvir during the establishment of the corresponding International Chemical Reference Standard and to use this value for the calculation of the test result.]

**Related substances.** Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a column (150 mm x 4.6 mm) packed with end-capped, base deactivated particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (3.5 μm).² Use the following conditions for gradient elution:

As mobile phase A, use a mixture of 21 volumes of 0.05 % phosphoric acid (~1440 g/L) TS, 77 volumes of water R and 2 volumes of acetonitrile R. As mobile phase B, use a mixture of 21 volumes of 0.05 % phosphoric acid (~1440 g/L) TS and 79 volumes of acetonitrile R.

Use the following gradient:

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 2.5</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
<tr>
<td>2.5 - 27.4</td>
<td>100 to 0</td>
<td>0 to 100</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>27.4 - 38</td>
<td>0</td>
<td>100</td>
<td>Isocratic</td>
</tr>
<tr>
<td>38 - 45</td>
<td>100</td>
<td>0</td>
<td>Re-equilibration</td>
</tr>
</tbody>
</table>

Operate with a flow rate of 1.5 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 260 nm. Maintain the column temperature at 30 °C.

Prepare the following solutions using as diluent a mixture of 50 volumes of mobile phase A and 50 volumes of mobile phase B. Prepare solution (1) as described under “Assay”. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3), dilute 5.0 mL of

² XSelect® C18 was found suitable.
solution (2) to 50.0 mL. For solution (4), dissolve 1.0 mg of sofosbuvir for peak identification RS (containing sofosbuvir and the impurities A, B, C, D and E) in 5.0 mL. For solution (5), dissolve 25.0 mg of phenol R and dilute to 50.0 mL. Dilute 2.0 mL of this solution to 100.0 mL. Dilute 5.0 mL of this solution to 50.0 mL.

Inject 20 µL of solutions (3) and (4).

The test is not valid unless the peak-to-valley ratio (Hp/Hv) in the chromatogram obtained with solution (4) is at least $x^3$, where Hp is the height above the extrapolated baseline of the peak due to impurity A and Hv is the height above the extrapolated baseline at the lowest point of the curve separating this impurity from the peak due to sofosbuvir. Also, the test is not valid unless the signal-to-noise of the peak due to sofosbuvir in the chromatogram obtained with solution (3) is at least 10.

Inject alternately 20 µL each of solutions (1), (2) and (5).

Use the chromatograms obtained with solutions (4) and (5) and the relative retentions below to identify the peaks due to impurities D, 1, 2, 3, 4 and 5.

The impurities, if present, are eluted at the following relative retentions with reference to sofosbuvir (retention time about 16 minutes): impurity A about 0.98; impurity B about 1.05; impurity C about 1.41; impurity D about 0.38; impurity E about 0.93, impurity F about 1.13; impurity G about 1.57; impurity 1 about 0.21; impurity 2 about 0.45; impurity 3 about 0.61; impurity 4 about 0.65; impurity 5 about 0.72.

In the chromatogram obtained with solution (1):

- the area of any peak corresponding to impurity D, when multiplied by a correction factor of 0.5, is not greater than 0.2 times the area of the peak due to sofosbuvir in the chromatogram obtained with solution (2) (0.2 %);
- the area of any peak corresponding to impurities 1, 2, 3 or 4 is not greater than 0.2 times the area of the peak due to sofosbuvir in the chromatogram obtained with solution (2) (0.2 %);

3 A value for the Hp/Hv has to be determined based on the available sofosbuvir for peak identification RS.
• the area of any peak corresponding to impurity 5 is not greater than the area of the peak due to phenol in the chromatogram obtained with solution (5) (0.2 %).

• The sum of the corrected area of any peak corresponding to impurity D and the areas of any peak corresponding to impurities 1, 2, 3 or 4 is not greater than the area of the peak due to sofosbuvir in the chromatogram obtained with solution (2) (1.0 %). Disregard any peak with an area less than the area of the peak due to sofosbuvir in the chromatogram obtained with solution (3) (0.1 %).

**Assay.** Carry out the test as described under 1.14.4 *High-performance liquid chromatography* using the conditions given under “Related substances” with the following modifications:

As the mobile phase use a mixture of 65 volumes of mobile phase A and 35 volumes of mobile phase B.

Prepare the following solutions using the mobile phase as diluent. For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, nominally containing 125.0 mg of sofosbuvir, to a 250 mL volumetric flask. Add about 200 mL of diluent and sonicate for 10 minutes, cool to room temperature, dilute to volume and filter. For solution (2), dilute 50.0 mg of sofosbuvir RS and dilute to 100.0 mL.

Inject alternatively 20 µL each of solutions (1) and (2). Record the chromatograms for 20 minutes.

Measure the areas of the peaks corresponding to sofosbuvir obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of sofosbuvir (C\textsubscript{22}H\textsubscript{29}FN\textsubscript{3}O\textsubscript{9}P), using the declared content of C\textsubscript{22}H\textsubscript{29}FN\textsubscript{3}O\textsubscript{9}P in sofosbuvir RS.

**Impurities.** The impurities limited by the requirements of this monograph include the impurities listed in the monograph for sofosbuvir and the impurities 1, 2, 3, 4 and 5.
1. (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine 5'-(dihydrogen phosphate) (fluoro uridine phosphate) (degradation product).

2. N-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy)(hydroxy)phosphoryl]-L-alanine (uridine alanine phosphate) (degradation product),

3. (2'R)-2'-deoxy-2'-fluoro-5'-O-[hydroxy(phenox)phosphoryl]-2'-methyluridine (uridine phenyl phosphate) (degradation product),

4. propan-2-yl N-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy)(hydroxy)phosphoryl]-L-alaninate (uridine isopropyl alanine phosphate) (degradation product),

5. phenol (degradation product).

Reference substances invoked

Sofosbuvir RS
International Chemical Reference Substance (ICRS) to be established.

Sofosbuvir for peak identification RS (containing sofosbuvir and the impurities A, B, C, D and E)

International Chemical Reference Substance (ICRS) to be established.

***